These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25609999)

  • 21. Oral contraceptive use and protective behavior after missed pills.
    Oakley D; Potter L; de Leon-Wong E; Visness C
    Fam Plann Perspect; 1997; 29(6):277-9, 287. PubMed ID: 9429874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone.
    Huber J; Foidart JM; Wuttke W; Merki-Feld GS; The HS; Gerlinger C; Schellschmidt I; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Mar; 5(1):25-34. PubMed ID: 10836660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People's Republic of China: a comparison with international studies.
    Marr J; Huang Z; Wang B; Zhang H; Roth K
    Open Access J Contracept; 2015; 6():95-104. PubMed ID: 29386927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy.
    Wiegratz I; Stahlberg S; Manthey T; Sänger N; Mittmann K; Lange E; Mellinger U; Palombo-Kinne E; Kuhl H
    Contraception; 2011 Aug; 84(2):133-43. PubMed ID: 21757054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quadriphasic versus monophasic oral contraceptives for contraception.
    Van Vliet HA; Raps M; Lopez LM; Helmerhorst FM
    Cochrane Database Syst Rev; 2011 Nov; (11):CD009038. PubMed ID: 22071862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
    Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
    Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A clinical comparison of two triphasic oral contraceptives with levonorgestrel or norethindrone: a prospective, randomized, single-blind study.
    Masson S; Franssen E; Hilditch JR; Powell MG
    Contraception; 1993 Jan; 47(1):43-54. PubMed ID: 8436001
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
    Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
    Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route.
    Coutinho EM; O'Dwyer E; Barbosa IC; Gu ZP; Shaaban MM; Aboul-Oyoon M; Abdel Aleem H
    Contraception; 1995 Jun; 51(6):355-8. PubMed ID: 7554976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of an ascending-dose, extended-regimen levonorgestrel/ethinyl estradiol combined oral contraceptive.
    Portman DJ; Kaunitz AM; Howard B; Weiss H; Hsieh J; Ricciotti N
    Contraception; 2014 Apr; 89(4):299-306. PubMed ID: 24576794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of the cycle control, safety, and efficacy profile of a 21-day regimen of ethinylestradiol 20mug and drospirenone 3mg with a 21-day regimen of ethinylestradiol 20mug and desogestrel 150mug.
    Gruber DM; Huber JC; Melis GB; Stagg C; Parke S; Marr J
    Treat Endocrinol; 2006; 5(2):115-21. PubMed ID: 16542051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
    Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception.
    Edelman AB; Gallo MF; Jensen JT; Nichols MD; Schulz KF; Grimes DA
    Cochrane Database Syst Rev; 2005 Jul; (3):CD004695. PubMed ID: 16034942
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women.
    Suthipongse W; Taneepanichskul S
    Contraception; 2004 Jan; 69(1):23-6. PubMed ID: 14720615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
    Boschitsch E; Skarabis H; Wuttke W; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Improving oral contraception compliance. The "ringing card": memory aid or new ritual?].
    Lachowsky M; Levy-Toledano R
    Gynecol Obstet Fertil; 2000 Apr; 28(4):317-23. PubMed ID: 10859894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
    Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
    Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.
    Foidart JM; Wuttke W; Bouw GM; Gerlinger C; Heithecker R
    Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):124-34. PubMed ID: 10943575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.